leisure time -WSS

leisure time

author：entertainment 2025-09-30 12:17:02 - browse：2495

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： ProMED sees offers of support, but its future remains unclear

entertainment

WSS

Evacuations in place as 3 wildfires burn in eastern Washington state

Clinical trials must include more disabled people

A new nitrogen execution bill also undermines medical licensing

Cancer drug shortages' outsize impact on ovarian cancer patients

Antivenom research: Lessons from HIV applied in search for universal antidote

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Clinical trials must include more disabled people

Alkermes shareholders re

Trump's false claims about Georgia's 2020 election long debunked

At least 13 dead in Texas as scorching temps continue

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Malaria cases in Florida and Texas: Here’s what you need to know

Majority of Americans think Trump's Ga. election interference case is serious: POLL

How one medical school became remarkably diverse

He's a Nobel laureate. Critics say he was misleading on Covid

focus

Obesity drugs seen as possible treatment for liver disease MASH

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

6 phony surgeries that take placebo to the extreme

Clinical trials must include more disabled people

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Hilary expected to bring catastrophic, life

hotspot

focus

entertainment

leisure time